Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Peter Rohr"'
Autor:
Lauren T. Hotaki, Anu Shrestha, Monica P. Bennett, Ivelisse L. Valdes, Sso H. Lee, Yinghua Wang, Dianne Spillman, Tina MacAulay, Melissa Hunt, Julie Gervais, Maral Mafi, Vincent Panetta, Yee Hoo Looi, Michael Shum, Eiman Atiek, Ricarda Meincke, Ulrich-Peter Rohr, Denize Ainbinder, Anat Boehm-Cagan, Osnat Luxenburg, Mateus Rodrigues Cerqueira, Laila Sofia Mouawad, Maria Fernanda Reis e Silva Thees, Krishna Prasad, R. Angelo de Claro
Publikováno v:
Therapeutic Innovation & Regulatory Science.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4451f294c06981a0a3e225302946f633
https://doi.org/10.1007/s43441-023-00522-4
https://doi.org/10.1007/s43441-023-00522-4
Autor:
Harpreet Singh, Julia A. Beaver, Richard Pazdur, Dianne Spillman, Nataliya Fesenko, Ulrich-Peter Rohr, Arūnas Girčys, Qiuyi Choo, Aleksandr Gamarian, Elitza Palazov, Jeanne Fourie Zirkelbach, Jiang Liu, Yangbing Li, Huiming Xia, Yuan Li Shen, Pallavi S. Mishra-Kalyani, Xiaoxue Li, Nicole Drezner, Paz J. Vellanki, Abigail L. Koch
Lung Cancer Staging per AJCC 7th and 8th Editions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02ea844594f3376770c9d06602668779
https://doi.org/10.1158/1078-0432.22484015
https://doi.org/10.1158/1078-0432.22484015
Autor:
Elitza Palazov, Yangbing Li, Harpreet Singh, Jeanne Fourie Zirkelbach, Julia A. Beaver, Dianne Spillman, Arūnas Girčys, Jiang Liu, Aleksandr Gamarian, Huiming Xia, Qiuyi Choo, Paz J. Vellanki, Pallavi S. Mishra-Kalyani, Nataliya Fesenko, Nicole Drezner, Ulrich-Peter Rohr, Richard Pazdur, Yuan Li Shen, Xiaoxue Li, Abigail L. Koch
Publikováno v:
Clinical Cancer Research. 27:6638-6643
On December 18, 2020, the FDA approved osimertinib as adjuvant therapy in patients with non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. The approval was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06a1241c1d69de4d61a6f32a05dbe4e2
https://doi.org/10.1158/1078-0432.ccr-21-1034
https://doi.org/10.1158/1078-0432.ccr-21-1034
Autor:
Gustavo Mendes Lima Santos, Agnes Chan, Lauren Tesh Hotaki, Kelly Robinson, Dianne Spillman, Laila Sofia Mouawad, Melissa Hunt, Michael Shum, Clare Rodrigues, Ulrich-Peter Rohr, R. Angelo de Claro, Chantal Walther, Richard Pazdur, Yee Hoo Looi, Caroline Healy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(24)
In 2019, the FDA Oncology Center of Excellence launched Project Orbis, a global collaborative review program to facilitate faster patient access to innovative cancer therapies across multiple countries. Project Orbis aims for concurrent submission, r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf61528403f1cc31027eebfdf21cbef5
https://pubmed.ncbi.nlm.nih.gov/33037016
https://pubmed.ncbi.nlm.nih.gov/33037016
Autor:
Jeanne Tie, Andrea Muranyi, Michael Christie, Paul Michael Waring, Peter Gibbs, Rebecca Bowermaster, Sabine Lohmann, Pia Herrmann, Susen Burock, Katharina Ilm, Janice Smith, Astrid Reiser, Ulrike Stein, Patrick Brunhoeber, Hai Zhang, Marc Osterland, Shalini Singh, Hui-Li Wong, Ulrich-Peter Rohr, Katherine Leith, Kandavel Shanmugam
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 28(8)
Background We assessed the novel MACC1 gene to further stratify stage II colon cancer patients with proficient mismatch repair (pMMR). Patients and methods Four cohorts with 596 patients were analyzed: Charite 1 discovery cohort was assayed for MACC1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22a8bf75641a13ca27a50661396568ad
https://pubmed.ncbi.nlm.nih.gov/28549076
https://pubmed.ncbi.nlm.nih.gov/28549076
Publikováno v:
Drug Discovery Today: Therapeutic Strategies. 10:e175-e181
A greater understanding of disease biology processes, the opportunity to develop targeted drugs leading to further improved patient outcomes and technology advances, as well as increasing pressure on healthcare budgets have led to a shift towards per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f0a1e3a0c4a6162f04f0e2d85090e44
https://doi.org/10.1016/j.ddstr.2013.05.002
https://doi.org/10.1016/j.ddstr.2013.05.002
Autor:
Rodrigo Jover, Zhiming Liao, Matthew Croxford, Rebecca Bowermaster, Song Hu, Jayesh Desai, Bonnie LaFleur, Andrea Muranyi, Ulrich-Peter Rohr, Peter Gibbs, Patrick Brunhoeber, Shalini Singh, Yifei Zhu, Ian T. Jones, Jeanne Tie, Pradipta Ghosh, R. Ridder, Volker Teichgräber, Ben Tran, Ajay Goel, Katherine Leith, Paul Waring, Kandavel Shanmugam
Publikováno v:
CLINICAL CANCER RESEARCH
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 22, iss 14
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 22, iss 14
r-FISABIO. Repositorio Institucional de Producción Científica
Purpose: Prognostic markers that identify patients with stage II colon cancers who are at the risk of recurrence are essential to personalize therapy. We evaluated the potential of GIV/Girdin as a predictor of recurrence risk in such patients. Experi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ad4040dc0cba7edd9e26ea79b93287f
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1400
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1400
Autor:
Carlo Guiseppe Mario Messina, Eduard Toerien, Francesco Giusti, Carmen Binder, Hans Hendrik Schäfer, Holger Moch, Ulrich-Peter Rohr, Thomas Dieterle
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0149856 (2016)
PLoS ONE
PLoS ONE
Background In vitro diagnostic (IVD) investigations are indispensable for routine patient management. Appropriate testing allows early-stage interventions, reducing late-stage healthcare expenditure (HCE). Aim To investigate HCE on IVDs in two develo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df2438b2451f8273f0e99c736d65682b
http://europepmc.org/articles/PMC4778800?pdf=render
http://europepmc.org/articles/PMC4778800?pdf=render
Autor:
Jonas Wiedemann, Eric Van Cutsem, Jim Cassidy, Leonard B. Saltz, Herbert Hurwitz, Florin Sirzen, Gary H. Lyman, Ulrich-Peter Rohr
Publikováno v:
Journal of Clinical Oncology. 29:1757-1764
Purpose Thromboembolism is a major source of morbidity and mortality in patients with cancer. The contribution of anti–vascular endothelial growth factor therapy to these events remains controversial. Patients and Methods Individual patient data we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65c3d478a24ce5a3740fe7b2919f9179
https://doi.org/10.1200/jco.2010.32.3220
https://doi.org/10.1200/jco.2010.32.3220
Autor:
Jim Cassidy, Fairooz F. Kabbinavar, Ulrich-Peter Rohr, Bruce J. Giantonio, Herbert Hurwitz, Leonard B. Saltz
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Cassidy, James; Saltz, Leonard B.; Giantonio, Bruce J.; Kabbinavar, Fairooz F.; Hurwitz, Herbert I.; & Rohr, Ulrich-Peter. (2010). Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Journal of Cancer Research and Clinical Oncology, 136(5), pp 737-743. doi: 10.1007/s00432-009-0712-3. Retrieved from: http://www.escholarship.org/uc/item/5mc303k2
Cassidy, James; Saltz, Leonard B.; Giantonio, Bruce J.; Kabbinavar, Fairooz F.; Hurwitz, Herbert I.; & Rohr, Ulrich-Peter. (2010). Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Journal of Cancer Research and Clinical Oncology, 136(5), pp 737-743. doi: 10.1007/s00432-009-0712-3. Retrieved from: http://www.escholarship.org/uc/item/5mc303k2
Background Bevacizumab is frequently combined with 5-fluorouracil-based chemotherapy for patients with metastatic colorectal cancer (mCRC). The relative benefit of bevacizumab in older patients has not been widely studied and is of interest. Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa8a995fc0831ff73fee430a2cee8592
http://europepmc.org/articles/PMC2841755
http://europepmc.org/articles/PMC2841755